Kornimate/medical-research-clean huggingface dataset:
adjuvant therapy with thalidomide for chemoembolization in advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: chemoembolization (tace) is used in the majority of advanced hepatocellular carcinomas. randomized clinical trials indicated that tace improves overall survival in patients with good liver function (child-pugh a or b). however, the shortcoming of tace is obvious: hypoxia induced neoangiogenesis after blockage of blood supply of the tumor; repeat tace deteriorates liver cirrhosis due to toxicity of chemotherapeutic agent to the parenchyma liver. thalidomide has been reported to have antiangiogenic and antimetastatic effects. the objectives of adjuvant therapy with thalidomide for chemoembolization is to evaluate overall survival and time to progression.


Eligibility criteria:
inclusion criteria: * hepatocellular carcinoma confirmed with pathology or identified with radiological images with typical features * age ≥ 18 years and ≤ 80 years * at least one tumor nodule with one uni-dimension of ≥ 2 cm * child-pugh class a or b * total bilirubin ≤ 1.5 x upper limit of normal * alt and ast ≤ 2.0 x the upper limit of normal * pt-inr\<2.3,ptt \< 1.5 x upper limit of normal * serum creatinine ≤ 1.5x upper limit of normal * peripheral white blood cell count of or more than 3×10(9)/l * peripheral platelet of or more than 50×10(9)/l * expected survival time not less than 3 months * ecog score 0-2 exclusion criteria: * tumor thrombi in main branch of portal vein * tumor involvement more than 70% of whole liver * with extrahepatic metastasis * prior systemic chemotherapy or chemoembolization * congestive heart failure \> nyha class 2 * history of hiv infection * active clinically serious infections (\> 2 nci-ctc version 3.0) * recurrence of hcc after liver transplantation * pregnant or breast-feeding * substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in this study * known or suspected allergy to any agent given in association with this trial * patients unable to swallow oral medication * inclined to thrombosis * inclined to hemorrhage or active hemorrhage with 1 month

Keywords: hepatocellular carcinoma thalidomide tace child-pugh class a or b
gastric cancer risk factors associated with eu and celac populations

Conditions: Cancer, Gastric

Summary: the study uses a case-control design that examines the differences in types of exposures between cases defined with a pathological confirmation of gc diagnosis, and controls, defined as patients to whom a gastroscopy was indicated and confirmed absent of gc i

gc is associated to several known risk factors. epidemiological and molecular features of gcs can vary widely. the reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium helicobacter pylori (h. pylori), epstein barr virus infection, dietary factors and others. these factors can influence gc outcomes. there is little knowledge regarding how these risk factors are associated with gc in celac and eu populations. the primary objectives of this study are to: 1. identify risk factors associated with gc in the celac and eu populations participating in this study including argentina, spain, mexico, netherlands, chile, portugal and paraguay. 2. identify clinical, demographic, and epidemiological differences among the populations participating in this study

Eligibility criteria:
cases * inclusion criteria * subjects ≥18 years old. * gc diagnosis (including gastroesophageal junction cancer) from ipatimup, incan, vumc, puc, vhio, iaf, incliva and genpat centres, in the last six months before his/her inclusion in the study. * has given and signed the ic to participate in this study. * exclusion criteria: * patients diagnosed with gc (including gastroesophageal junction cancer) from other centres/ countries not participating in this proposal. * patients with suspected with gc diagnosis but not confirmed by the pathological report. controls * inclusion criteria * subjects ≥18 years old. * subjects to whom a gastroscopy was indicated in its medical care and confirmed absent of gc in the same centres will be matched in age (+/- 10 years), gender and pertaining from the same region of the gc case. thus, to match our gc cases same number of controls is expected to be recruited. * has given and signed the ic to participate in this study. * exclusion criteria: * subjects from a different geographic area from the cases. * patients with high suspicion of gc (including gastroesophageal junction cancer) or previous personal history known of document chronic gastritis diagnosed by endoscopy and confirmed by histology.

Keywords: gastric cancer personalized medicine oncology solid tumor primary intervention
surgisis anal fistula plug study: an experience in saudi arabia

Conditions: Anal Fistula

Summary: the surgisis anal fistula plug study is a clinical trial conducted in saudi arabia to study the safety and effectiveness of the surgisis afp plug in the treatment of chronic anal fistulas.

up to 30 patients will be treated with the surgisis anal fistula plug using a standardized surgical procedure to plug their anal fistula. patients will be followed periodically until their 12-month follow-up.

Eligibility criteria:
inclusion criteria: * 18 years old or older * primary, persistent, or recurrent fistula tract that is either transsphincteric, suprasphincteric, or extrasphincteric * signed informed consent * willing to return for follow-up visits exclusion criteria: * crohn's disease * ulcerative colitis * hiv positive * immune system disorder * collagen disorder * tuberculosis * history of radiation to anorectal region * allergies to pig tissue * religious or cultural objection to use of pig tissue in this surgical application * j-pouch fistulas * previous surgisis afp plug placement in target fistula tract * tracts with acute abscess, infection or inflammation * superficial fistula tracts conventionally treated with fistulotomy/fistulectomy

Keywords: fistula anal fistula
patients who receive 131 i-mibg

Conditions: Brain and Nervous System

Summary: this study is for patients who have have neuroblastoma, pheochromocytoma, or paraganglioma that has come back (relapsed) after treatment or has not gotten better (refractory) with standard treatment. the purpose of this study is to evaluate quality of life and response rate to 131 i-mibg treatment.

this is an observational, single institution study designed to determine the benefit of 131i-mibg therapy in subjects with refractory, relapsed or progressive neuroblastoma, malignant pheochromocytoma or paraganglioma, or other neuroendocrine tumors. response rate, time to progression, and quality of life changes will be evaluated.

Eligibility criteria:
inclusion criteria subject must meet all of the following applicable inclusion criteria to participate in this study: 1. written informed consent, and assent where applicable, and hipaa authorization for release of personal health information. note: hipaa authorization may be included in the informed consent or obtained separately. 2. age greater than or equal to 1 years and less than or equal to 30 years at the time of therapy. 3. subject is scheduled to receive 131 i-mibg therapy. 4. diagnosis of refractory, progressive or relapsed neuroblastoma, malignant paraganglioma, malignant pheochromocytoma or other neuroendocrine tumors. 5. as determined by the enrolling physician, ability of the subject and parent/caregiver to understand and comply with study procedures for the entire length of the study. exclusion criteria subjects meeting the criteria below may not participate in the study: 1. prior enrollment on lci-ped-neu-mibg-001 trial.
care-related pain and discomfort in people with motor disorder

Conditions: Motor Disorders; Pain

Summary: the combination of motor disabilities, chronic pain, cognitive disabilities limiting the possibilities of communications and repeated potentially painful rehabilitation, exposes patients with motor disabilities to a high risk of induced pain in the specialized establishments. induced pain is difficult to detect and is therefore little assessed and treated. currently, little is known about the prevalence and conditions of occurrence of such induced pain as the clinical characteristics of patients (children, adults, severity of disability), the types of care and the nature of the institutional admission (medical or medico-social). secondary objectives are to identify risk factors related to the induced pain and patient characteristics, as well as to create an easy-to-use weekly continuous pain assessment tool in a routine clinical set-up. all daily life procedures or treatment carried out in children and adults with motor disability are collected for 5 days and 1 night. collected data are clinical and demographic characteristics of patients, the intensity of the pain assessed by the care professional (flacc-r) or the patient himself (vas). clinically, the uncomfortable and painful procedures and risk factors for pain identified by this study will help the development of targeted preventive measures within institutions. meanwhile, the study should sensitize breton teams involved with regards to the induced pain, leading them to observe the behavior of patients, to admit any pain related to an act of daily life, and to ask for the medical profession to anticipate the painful experience.


Eligibility criteria:
inclusion criteria: * motor disorder * institutionalized exclusion criteria: * chronical pain
predm clinical decision support intervention

Conditions: PreDiabetes

Summary: clinical practice guidelines recommend intensive lifestyle interventions and metformin to prevent or delay type 2 diabetes; yet these treatments are not routinely used among the 86 million u.s. adults with prediabetes who may benefit from them. while clinical decision support (cds) represents an effective approach for delivering guideline-based care, the potential of this strategy to improve diabetes prevention efforts has not been definitively tested. this study developed the novel prevent diabetes mellitus clinical decision support (predm cds) intervention and evaluated its impact on clinical outcomes.

eighty six million u.s. adults have prediabetes, and up to 75% of them will eventually develop diabetes. landmark clinical trials have established that intensive lifestyle interventions (ili) and metformin are safe and effective treatments to prevent or delay diabetes in adults with prediabetes and overweight/obesity. despite being included in expert clinical guidelines, these treatments are rarely used and few studies have explored how to promote their uptake in practice. one possible approach for increasing adoption of ili and metformin in primary care includes clinical decision support (cds), which uses electronic systems to create tailored recommendations for evidence-based clinical care. while a large body of evidence demonstrates that cds can improve the delivery of other recommended preventive services, this approach has not been definitively studied for ili and metformin. the investigators plan to address this critical knowledge gap by developing and evaluating the prevent diabetes mellitus clinical decision support (predm cds) intervention for community health center patients with prediabetes and overweight/obesity. this novel cds engages primary care providers and clinical staff to deliver intervention components. this study tests the potential for cds to promote diabetes prevention and weight loss efforts in primary care. the current study objectives were to: 1) interview providers about their preferences for cds focused on prediabetes; 2) develop a novel cds tool, the prediabetes cds (predm cds), promoting evidence-based care for prediabetes; and 3) conduct a pilot evaluation of the novel cds tool using electronic health record data. study investigators hypothesize that the proposed predm cds will increase patient's adoption of ili and metformin, producing modest weight loss and improvements in other cardiometabolic markers.

Eligibility criteria:
inclusion criteria: * age ≥18 years old * prediabetes * two weight measurements during the study period exclusion criteria: * the primary exclusion criterion is type 2 diabetes. * the following additional criteria will exclude those in whom treatment is potentially harmful or outcomes assessment may be confounded: serum creatinine \>1.4mg/dl in women and \>1.5mg/dl in men, uncontrolled hypertension (≥180/100mmhg), prior antidiabetic medication orders, and gastric bypass surgery or pregnancy during the evaluation period.
the efficacy of cimetidin for acute - extrinsic atopic dermatitis treated with standard therapy

Conditions: Atopic Dermatitis; Immunoglobulin E Concentration, Serum

Summary: extrinsic - atopic dermatitis is characterized by increased of ige serum levels. acute extrinsic - atopic dermatitis is a type 1 hypersensitivity that involve various inflammatory mediator including interleukin-4, interleukin-12, and interferon-ɣ. recent treatment of atopic dermatitis mainly focused on reducing the inflammation through topical and systemic regiments. however, no systemic medication could control the atopic dermatitis remission yet, and the current immunosuppressive agent used may cause many side effects if administered on a long term basis. in the future, treatment of atopic dermatitis were specifically targeted to inhibit the role of th2. cimetidine is h2 receptor antihistamine that has been widely used as gastrointestinal medication for a long time. cimetidine could modulate the immune system by activating the th1 and lowering the th2 activity, and lowering the ige levels thus reducing the severity of atopic dermatitis.

the aim of this study is to measure the efficacy of cimetidine for acute, extrinsic-atopic dermatitis treated with standard therapy using scorad as the clinical outcome. this study also measure immunoglobulin e, interleukin-4, interleukin-12, and interferon-ɣ serum levels before and after treatment.

Eligibility criteria:
inclusion criteria: * atopic dermatitis patients diagnosed with hanifin rajka criteria * acute extrinsic atopic dermatitis * ige levels above 200 iu/ml * minimum weight 15kg exclusion criteria: * consumption of corticosteroid and systemic immunosuppressant within the last 2 weeks * chronic lesion * consumption of drugs that reacts with cimetidine * disturbance in lab results including complete blood count, liver function, and renal function. * other conditions that might increase ige levels

Keywords: atopic dermatitis cimetidine immunoglobulin e interleukin-4 interleukin-12 interferon gamma scorad treatment
clinical study of the efficacy and safety of bcd-201 and keytruda in subjects with advanced melanoma

Conditions: Melanoma (Skin)

Summary: this clinical study is designed as a randomized, double-blind trial. subjects with unresectable, metastatic, or recurrent skin melanoma will be randomized to one of the two study groups (bcd-201 group and keytruda group) at a 1:1 ratio. the goal of this study is to compare the efficacy and safety of bcd-201 and keytruda as first-line therapy in subjects with unresectable, metastatic, or recurrent skin melanoma.


Eligibility criteria:
inclusion criteria: * signed informed consent; * histologically confirmed melanoma; * tumor first detected at the stage of advanced unresectable or metastatic disease, or disease progressing during or recurring after previous radical therapy; * ecog score 0-1; * at least one measurable lesion according to recist 1.1; * laboratory test results consistent with adequate functioning of systems and organs; * willingness of men and women of childbearing potential to use highly effective contraceptive methods from the signing of the informed consent form, throughout the study and for 6 months after the administration of the last product dose. exclusion criteria: * indications for radical therapy (surgery, radiation therapy); * uveal, ocular or mucosal melanoma; * active cns metastases and/or carcinomatous meningitis; * subjects with severe concomitant disorders, life-threatening acute complications of the primary disease; * concomitant diseases and/or conditions that significantly increase the risk of aes during the study; * active, known or suspected autoimmune disorders (subjects with type 1 diabetes mellitus or hypothyroidism requiring only hormone-replacement therapy and those with skin disorders \[vitiligo, alopecia, or psoriasis\] not requiring systemic therapy are eligible to participate); * the need for therapy with glucocorticoids or any other drugs with immunosuppressive effects within 14 days prior to randomization; * history of (non-infectious) pneumonitis requiring glucocorticoid therapy or pneumonitis at the time of screening; * hypersensitivity or allergy to any of the pembrolizumab product components; * pregnancy or breastfeeding, as well as intention to become pregnant or father a child during the study period.
comparative clinical study between virtual reality hypnosis and nitrous oxide inhalation for dental anxie

Conditions: Dental Anxiety

Summary: the vicious circle of dental anxiety impacts major aspects of a child's quality of life. hypnosis using distraction is one of the most common non-pharmalogical techniques in behavior and pain management in pediatric dentistry. its value over traditional pharmalogical sedation is undeniable. this clinical study examines the application of hypnosis delivered through immersive virtual reality (vr) for anxious children ongoing dental procedures. the investigators will explore whether vr is as effective on pain and anxiety relief as a pharmacological sedation with inhalation of nitrous oxide.

the working hypothesis of this study is that hypnosis through virtual reality can reduce children's anxiety as well as their pain level during dental care with an efficiency and tolerance at least similar to nitrous oxide inhalation. specifically, the statistical analyses will be based on an assumption of non-inferiority of vr compared to the pharmacological technique of nitrous oxide sedation. each patient (aged from 6 to 10) attended for two visits in order to benefit of 2 similar conservative dental treatments on primary molars. everyone was randomly allocated to receive hypnosis through virtual reality or nitrous oxide/oxygen titrated to 50%/50% at the first visit, the alternative being used at the second visit. this randomization helps avoid any experimental bias related to a first positive or negative experience, each patient being its own control. vital signs and a video of the child's behavior are recorded for an external examinator. the video shows the child's body response as an indicator for his anxiety level through the procedures. the child's face doesn't appear on the video in order to reduce risks of bias.

Eligibility criteria:
inclusion criteria: * patients aged between 7 and 10 years * with an indication for conservative and/or endodontic care of at least 2 temporary molars belonging to the same dental arch, unilateral or bilateral, and equivalent in terms of caries and symptoms * with dental anxiety * asa i patients exclusion criteria: * patient with a history of meopa or virtual reality sedation for dental treatment * patient refusing to do preoperative intra-oral x-rays * patient with one of the meopa contraindications * patient with a history of post-operative nausea vomiting or motion sickness * patient with visual or hearing disorders * patient presenting with a psychiatric pathology or having taken psychotropic drugs in the 8 weeks preceding the 1st visit and during the duration of the study * patient with claustrophobia * patient without french social security coverage * lack of consent from the holders of parental authority to participate in the study

Keywords: virtual reality hypnosis nitrous oxide dental anxiety child
epidemiological analysis of vitamin d and breast cancer risk in saudi arabian women

Conditions: Breast Cancer; Vitamin D Deficiency

Summary: this is an analysis of de-identified data collected from 240 saudi arabian women, 120 with breast cancer and 120 control women, to evalyate if vitamin d status is associated with breast cancer risk.

background: the role of vitamin d in breast cancer prevention is equivocal. saudi arabian women are thought to be at greater risk for vitamin d deficiency due to darker skin type and greater likelihood for reduced uvb radiation exposure. however, there is a lack of data regarding the vitamin d status of saudi arabian women and how this may relate to breast cancer risk. objective: the purpose of this research was to evaluate the association between circulating concentrations of 25(oh)d and breast cancer risk in saudi arabian women. design: a case-control study was conducted among 120 breast cancer cases and 120 controls. the study population was drawn from patients admitted to king fahd hospital in jeddah, saudi arabia from june to august 2009. participants completed questionnaires on diet and medical history and serum samples were collected from all women to measure circulating 25(oh)d concentrations.

Eligibility criteria:
inclusion criteria: * invasive breast cancer (cases) or healthy women (controls), * receiving standard medical check-ups at the women's clinic * female, * between the ages of 18 and 75 years * bmi ≤ 40 kg/m2 * residence in saudi arabia for more than 5 years * absence of chronic diseases that could affect vitamin d metabolism, including renal, hepatic, endocrine, or autoimmune disease. exclusion criteria: receiving standard medical check-ups at the women's clinic * male, * less than 18 or greater than 75 years of age * bmi \> 40 kg/m2 * not a resident of saudi arabia for more than 5 years * presence of chronic diseases that could affect vitamin d metabolism, including renal, hepatic, endocrine, or autoimmune disease.

Keywords: breast cancer vitamin d 25 oh vitamin d
effect of 1.8-mm steep-axis clear corneal incision on the posterior corneal astigmatism in candidates for toric iol implantation

Conditions: Cataract

Summary: we aimed to analyze the effects of cataract surgery using a 1.8-mm steep-axis clear corneal incision (cci) on the posterior corneal surfaces based on the keratometry from the rotating scheimpflug imaging device (pentacam hr) in candidates for toric intraocular lens (iol) implantation

preoperative and at least 1-month postoperative data measured by pentacam hr were collected in patients for toric iol implantation. surgically induced astigmatism on the posterior cornea (p-sia) was calculated based on the preoperative and postoperative keratometric data, and the related factors of p-sia were analyzed.

Eligibility criteria:
inclusion criteria: 1. patients aged at least 45 years old who were scheduled for cataract surgery; (2) regular corneal astigmatism ≥ 1.0 d; (3) the imaging quality parameter (qs) of pentacam hr was "ok"; and (4) follow-up time ≥1.0 month. exclusion criteria:(1) irregular corneal astigmatism; (2) corneal scar, corneal degeneration, pterygium invading the optic zone; (3) corneal endothelium count\<1,000/mm2, corneal endothelial dystrophy, iritis, glaucoma and retinal disease; (4) history of eye surgery, such as corneal refractive surgery, corneal transplantation and retinal surgery; (5) the main incision was expanded or sutures were used during surgery; and (6) some postoperative complications, such as persistent corneal edema, descemet's membrane detachment and poor wound healing, and any others that might affect the measurement results of the pentacam hr during the follow-up period. -